Yakult Honsha Co. Ltd.

Germany’s 4SC faces an uncertain future after regulators in Europe dashed any hopes that Kinselby would become the first approved maintenance therapy for cutaneous T-cell lymphoma (CTCL). The Planegg-

After years of struggle, Yakult Honsha Co. Ltd. has decided to shrink its oncology portfolio and tighten the focus of its future pharmaceutical business on microbiome-related therapies. The diversi

The recent concerns in the US over the risk-benefit balance for phosphatidylinositol 3-kinase (PI3K) inhibitors have cast a new shadow over the pharmaceutical business of diversified Japanese firm Ya

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions. Aevi Obtains Option For AstraZ